Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/aster-dm-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:23662:1" rel="noopener">Aster DM Healthcare Ltd (ASTERDM IN)</a> reported double-digit growth in revenue and EBITDA in Q2FY26, led by substantial recovery in Kerala, strong growth in international revenue, and better case mix.</li>
<li>In Q2FY26, Kerala delivered its highest-ever quarterly revenue of INR6B, growing 24% increase over Q4 FY25. Profitability improved sharply, with EBITDA margins expanding to 26.8% from 22.3% in Q4FY25.</li>
<li>Since our initiation of Aster DM as ‘2025 High Conviction’ idea in last November, shares rose ~55%. Main investment thesis of margin improvement still holds good.</li>
</ul>



Aster DM Healthcare Ltd (ASTERDM IN) reported double-digit growth in revenue and EBITDA in Q2FY26, led by substantial recovery in Kerala, strong growth in international revenue, and better case mix.
In Q2FY26, Kerala delivered its highest-ever quarterly revenue of INR6B, growing 24% increase over Q4 FY25. Profitability improved sharply, with EBITDA margins expanding to 26.8% from 22.3% in Q4FY25.
Since our initiation of Aster DM as ‘2025 High Conviction’ idea in last November, shares rose ~55%. Main investment thesis of margin improvement still holds good.


2025 High Conviction Update: Aster DM (ASTERDM IN)- Stable Q2 Show on Continued Business Recovery

Event-Driven

<ul>
<li>SEBI has approved IHH Healthcare’s open offer for acquisition of up to 26% stake in <a href="https://www.smartkarma.com/entities/fortis-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:881:1" rel="noopener">Fortis Healthcare (FORH IN)</a>. If materializes, this should uplift IHH’s holding in Fortis to 57%.</li>
<li>In 2018, Fortis' original open offer price was INR170 per share, and the offer size was INR33B. Currently, Fortis share is trading at INR1,054, up more than 6x since 2018.</li>
<li>IHH will make appropriate announcement ‘in a timely manner’, which should provide clarity on open offer pricing. Unless an attractive revised price is announced, the shareholders acceptance will be limited.</li>
</ul>


SEBI has approved IHH Healthcare’s open offer for acquisition of up to 26% stake in Fortis Healthcare (FORH IN). If materializes, this should uplift IHH’s holding in Fortis to 57%.
In 2018, Fortis' original open offer price was INR170 per share, and the offer size was INR33B. Currently, Fortis share is trading at INR1,054, up more than 6x since 2018.
IHH will make appropriate announcement ‘in a timely manner’, which should provide clarity on open offer pricing. Unless an attractive revised price is announced, the shareholders acceptance will be limited.


Fortis Healthcare (FORH IN): Indian Regulators Cleared Long-Awaited Open Offer of IHH

<ul>
<li>
<a href="https://www.smartkarma.com/entities/aster-dm-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:23662:1" rel="noopener">Aster DM Healthcare Ltd (ASTERDM IN)</a> reported 8% revenue growth in Q1FY26, driven by a 14% rise in ARPOB and 4% reduction in ALOS. EBITDA margin expanded 230bps to 20.0%.</li>
<li>Kerala revenue grew 5% as compared with 4% decline in Q4FY25, driven by 6% QoQ increase in-patient volumes and 200 bps QoQ increase in occupancy, reflecting early signs of recovery.</li>
<li>Q1FY26 results ensure that the momentum is back. With strong base business, proposed merger with QCIL, and expansion plan, Aster DM is well-positioned for 20%+ revenue growth through FY28.</li>
</ul>



Aster DM Healthcare Ltd (ASTERDM IN) reported 8% revenue growth in Q1FY26, driven by a 14% rise in ARPOB and 4% reduction in ALOS. EBITDA margin expanded 230bps to 20.0%.
Kerala revenue grew 5% as compared with 4% decline in Q4FY25, driven by 6% QoQ increase in-patient volumes and 200 bps QoQ increase in occupancy, reflecting early signs of recovery.
Q1FY26 results ensure that the momentum is back. With strong base business, proposed merger with QCIL, and expansion plan, Aster DM is well-positioned for 20%+ revenue growth through FY28.


2025 High Conviction Update: Aster DM (ASTERDM IN)- Starts FY26 On High Note; Announces New Hospital

External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Krishna Institute of Medical Sciences / Equity Bottom-Up

Krishna Institute of Medical Sciences (KIMS IN)

<ul><li>Operational Performance: Consolidated occupancy declined by 340bps YoY and 267bps QoQ to 48%.</li><li>However, ARPOB rose 21.6% YoY and 8.3% QoQ to Rs 41,669 in Q4FY25, supported by new bed additions, a better case mix, and revised pricing through TPA negotiations. </li><li>Margins and Profitability: EBITDA margins remained stable at 24.8% YoY but declined 61bps QoQ due to lower OPEX. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Operational Performance: Consolidated occupancy declined by 340bps YoY and 267bps QoQ to 48%.However, ARPOB rose 21.6% YoY and 8.3% QoQ to Rs 41,669 in Q4FY25, supported by new bed additions, a better case mix, and revised pricing through TPA negotiations. Margins and Profitability: EBITDA margins remained stable at 24.8% YoY but declined 61bps QoQ due to lower OPEX. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences Ltd - Growth to Be Driven by ARPOB

<ul>
<li>
<a href="https://www.smartkarma.com/entities/aster-dm-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:23662:1" rel="noopener">Aster DM Healthcare Ltd (ASTERDM IN)</a> reported stellar performance in Q3FY25. Revenue achieved 11% YoY growth to INR10.5B, driven by increased patient volumes and growth in ARPOB. </li>
<li>Consistent growth across core businesses, combined with strategic cost optimization, operational efficiencies, and optimized service mix, have significantly strengthened margins, with Q3FY25 operating EBITDA margins standing at 19.3% (Q3FY24: 17.7%).</li>
<li>Our original investment thesis is intact. Margin levers are working well. Expansion plan is on track. Macro trend is favorable. Merger with Quality Care can be a game changer.</li>
</ul>



Aster DM Healthcare Ltd (ASTERDM IN) reported stellar performance in Q3FY25. Revenue achieved 11% YoY growth to INR10.5B, driven by increased patient volumes and growth in ARPOB. 
Consistent growth across core businesses, combined with strategic cost optimization, operational efficiencies, and optimized service mix, have significantly strengthened margins, with Q3FY25 operating EBITDA margins standing at 19.3% (Q3FY24: 17.7%).
Our original investment thesis is intact. Margin levers are working well. Expansion plan is on track. Macro trend is favorable. Merger with Quality Care can be a game changer.


2025 High Conviction Update: Aster DM Healthcare (ASTERDM IN) Q3 Result- Margin Expansion Continues

India

Krishna Institute of Medical Sciences (KIMS) is an Indian multi-speciality hospital chain that offers a comprehensive range of healthcare services across various medical and surgical specialties, including cardiac sciences, oncology, neurosciences, orthopaedics, and organ transplantation. KIMS operates a network of hospitals providing multidisciplinary integrated tertiary and quaternary healthcare. The company is headquartered in Secunderabad, India, and was founded in 2000.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Krishna Institute of Medical Sciences (KIMS IN)

2025 High Conviction Update: Aster DM (ASTERDM IN)- Stable Q2 Show on Continued Business Recovery

Aster DM reported double-digit revenue and EBITDA growth in Q2FY26, led by substantial recovery in Kerala and better case mix. Kerala delivered its...

Tina Banerjee

Fortis Healthcare (FORH IN): Indian Regulators Cleared Long-Awaited Open Offer of IHH

SEBI has approved IHH Healthcare’s open offer for acquisition of up to 26% stake in Fortis Healthcare. If materializes, this should uplift IHH’s...

Tina Banerjee

2025 High Conviction Update: Aster DM (ASTERDM IN)- Starts FY26 On High Note; Announces New Hospital

Aster DM reported 8% revenue growth in Q1FY26, driven by increased ARPOB and reduced ALOS. Strong performance indicates momentum is back, with...

Tina Banerjee

Krishna Institute of Medical Sciences Ltd - Growth to Be Driven by ARPOB

Consolidated occupancy declined by 340bps YoY and 267bps QoQ to 48%. However, ARPOB rose 21.6% YoY and 8.3% QoQ to Rs 41,669 in Q4FY25

Axis Direct

2025 High Conviction Update: Aster DM Healthcare (ASTERDM IN) Q3 Result- Margin Expansion Continues

Aster DM achieved 11% revenue growth to INR10.5B in Q3FY25, with operating EBITDA margins standing at 19.3% (vs. Q3FY24: 17.7%). The company aims...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

2025 High Conviction Update: Aster DM (ASTERDM IN)- Stable Q2 Show on Continued Business Recovery

Aster DM reported double-digit revenue and EBITDA growth in Q2FY26, led by substantial recovery in Kerala and better case mix. Kerala delivered its...

Tina Banerjee

Fortis Healthcare (FORH IN): Indian Regulators Cleared Long-Awaited Open Offer of IHH

SEBI has approved IHH Healthcare’s open offer for acquisition of up to 26% stake in Fortis Healthcare. If materializes, this should uplift IHH’s...

Tina Banerjee

2025 High Conviction Update: Aster DM (ASTERDM IN)- Starts FY26 On High Note; Announces New Hospital

​Aster DM reported 8% revenue growth in Q1FY26, driven by increased ARPOB and reduced ALOS. Strong performance indicates momentum is back, with...

Tina Banerjee

Krishna Institute of Medical Sciences Ltd - Growth to Be Driven by ARPOB

Consolidated occupancy declined by 340bps YoY and 267bps QoQ to 48%. However, ARPOB rose 21.6% YoY and 8.3% QoQ to Rs 41,669 in Q4FY25

Axis Direct

2025 High Conviction Update: Aster DM Healthcare (ASTERDM IN) Q3 Result- Margin Expansion Continues

Aster DM achieved 11% revenue growth to INR10.5B in Q3FY25, with operating EBITDA margins standing at 19.3% (vs. Q3FY24: 17.7%). The company aims...

Tina Banerjee

Aster DM reported 8% revenue growth in Q1FY26, driven by increased ARPOB and reduced ALOS. Strong performance indicates momentum is back, with...